Sovateltide

DRACPC ID  DRACPC0015

Active Ingredients   Sovateltide

Description  A highly selective peptide agonist of the endothelin-B receptor. Sovateltide binds to endothelin-B receptors on endothelial cells in tumor blood vessels, which, unlike the angioarchitecture of normal blood vessels, are relatively devoid of smooth muscle. This agent may induce a transient, selective increase in blood flow to a tumor, which may result in an increase in the delivery of anticancer agents to the tumor and, so, an increase in anticancer agent efficacy.

Synonyms  SPI-1620; IRL-1620; Endothelin B Receptor Agonist SPI-1620; Sovateltide; PMZ-1620

Type  Small Molecule

Disease  Cancer/Tumor

Classification

  

Endothelin-B receptor agonist Peptide and derivative

Structure Information


Molecular Formula  C86H117N17O27

Molecular Weight  1820.9

Active Sequence  DEEAVYFAHLDIIW

Sequence Length  14

Modification  C-terminal Suc

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  N-(3-carboxypropanoyl)-L-alpha-aspartyl-L-alpha-glutamyl-L-alpha-glutamyl-L-alanyl-L-valyl-L-tyrosyl-L-phenylalanyl-L-alanyl-L-histidyl-L-leucyl-L-alpha-aspartyl-L-isoleucyl-L-isoleucyl-L-tryptophan

InChI  InChI=1S/C86H117N17O27/c1-11-44(7)71(84(127)100-63(86(129)130)35-50-39-88-54-21-17-16-20-53(50)54)103-85(128)72(45(8)12-2)102-82(125)62(38-69(114)115)98-78(121)57(32-42(3)4)96-80(123)60(36-51-40-87-41-89-51)95-73(116)46(9)91-77(120)58(33-48-18-14-13-15-19-48)97-79(122)59(34-49-22-24-52(104)25-23-49)99-83(126)70(43(5)6)101-74(117)47(10)90-75(118)55(26-29-65(106)107)93-76(119)56(27-30-66(108)109)94-81(124)61(37-68(112)113)92-64(105)28-31-67(110)111/h13-25,39-47,55-63,70-72,88,104H,11-12,26-38H2,1-10H3,(H,87,89)(H,90,118)(H,91,120)(H,92,105)(H,93,119)(H,94,124)(H,95,116)(H,96,123)(H,97,122)(H,98,121)(H,99,126)(H,100,127)(H,101,117)(H,102,125)(H,103,128)(H,106,107)(H,108,109)(H,110,111)(H,112,113)(H,114,115)(H,129,130)/t44-,45-,46-,47-,55-,56-,57-,58-,59-,60-,61-,62-,63-,70-,71-,72-/m0/s1

InChI_Key DXPHNGAMYPPTBJ-TZMIJSMNSA-N

SMILES  CC[C@@H]([C@@H](C(N[C@@H]([C@H](CC)C)C(N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12)=O)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](C(C)C)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CCC(O)=O)=O)CC(O)=O)=O)CCC(O)=O)=O)CCC(O)=O)=O)C)=O)=O)CC3=CC=C(C=C3)O)=O)CC4=CC=CC=C4)=O)C)=O)CC5=CNC=N5)=O)CC(C)C)=O)CC(O)=O)=O)C

External Codes


PubChem CID  16133819

DrugBank Accession Number  DB06138

NCI Thesaurus Code  C74027  

UNII  11X778QIZS   GSRS

CAS  142569-99-1



Drug approval


Drug indication
    Investigated for use/treatment in cancer/tumors (unspecified).

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT01741155 A 2-Part Phase 2 Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer After Failure of First-line Platinum-based Chemotherapy Non Small Cell Lung Cancer (NSCLC) Phase 2 Treatment
NCT01773785 Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line Treatment for Patients With Advanced Biliary Cancer Biliary Cancer Phase 2 Treatment
NCT00613691 A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma Carcinoma Phase 1 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DRACP is developed by Dr.Zheng's team.